Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds Combining Thermal Burn and Radiation Exposure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds Combining Thermal Burn and Radiation Exposure
April 23, 2015 12:25 PM EDT
Maxim Group analyst Jason Kolbert reiterated his Buy rating and $7 price target on Cytori Therapeutics, Inc. (NASDAQ: CYTX) after the company presented data from two preclinical studies funded through its contract with the United States Biomedical Advanced Research and Development Authority (BARDA) at the 2015 American Burn Association Meeting this week in Chicago.
Kolbert highlighted:
Cytori is moving ADRCs...
More
April 23, 2015 8:06 AM EDT
Cytori Therapeutics, Inc. (NASDAQ: CYTX) presented data from two preclinical studies funded through its contract with the United States Biomedical Advanced Research and Development Authority (BARDA) at the 2015 American Burn Association Meeting this week in Chicago. The findings provide greater detail as to how Cytori's cellular therapeutic improves healing following thermal burn injury even in subjects with substantial radiation exposure.
"Our data show that Cytori Cell Therapy acts at the cellular and molecular level to modulate different phases of wound healing thereby accelerating wound closure in clinically relevant large animal models. Treatment led to... More
